Company intelligence / Profile preview

Latticon Biopharmaceuticals

Gaithersburg, Maryland, United States

Ownership: Private
Development stage: Phase 1

Overview

Latticon is conducting a first-in-human, open-label, multicenter Phase 1/2 trial of its lead program LAT010 in patients with advanced solid tumors. The study aims to evaluate safety, tolerability, immunogenicity, pharmacokinetics/pharmacodynamics and preliminary efficacy. The IND for LAT010 was approved by the FDA in late 2023; as of early 2025 the trial is actively recruiting and no topline results have been reported yet.

Therapeutic areas: Oncology
Modalities: Antibody-based therapiesImmunocytokines (antibody-cytokine fusion proteins)
Industry: Biotech

Partnerships

Zencore Biologics – CMC/CDMO services provider supporting IND-enabling work for LAT010Laitekang (Suzhou) – Clinical development partner in ChinaNo major pharma partnerships publicly disclosed.

Beyond the preview

Go deeper on Latticon Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latticon Biopharmaceuticals.

Explore the full profile